IL-15 in the Combination Immunotherapy of Cancer

Thomas A Waldmann, Sigrid Dubois, Milos D Miljkovic, Kevin C Conlon, Thomas A Waldmann, Sigrid Dubois, Milos D Miljkovic, Kevin C Conlon

Abstract

We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56bright NK cells and a 5.8-fold increase in CD8 T cells. However, IL-15 preparations administered as monotherapy were ineffective, due to actions of immunological checkpoints and due to the lack of tumor specific targeting by NK cells. To circumvent checkpoints, trials of IL-15 in combination with other anticancer agents were initiated. Tumor-bearing mice receiving IL-15 with antibodies to CTLA-4 and PD-L1 manifested marked prolongation of survival compared to mice receiving IL-15 with either agent alone. In translation, a phase I trial was initiated involving IL-15 (rhIL-15), nivolumab and ipilimumab in patients with malignancy (NCT03388632). In rhesus macaques CIV IL-15 at 20 μg/kg/day for 10 days led to an 80-fold increase in number of circulating effector memory CD8 T cells. However, administration of γc cytokines such as IL-15 led to paralysis/depression of CD4 T-cells that was mediated through transient expression of SOCS3 that inhibited the STAT5 signaling pathway. This lost CD4 helper role could be restored alternatively by CD40 agonists. In the TRAMP-C2 prostate tumor model the combination of IL-15 with agonistic anti-CD40 produced additive effects in terms of numbers of TRAMP-C2 tumor specific Spas/SCNC/9H tetramer positive CD8 T cells expressed and tumor responses. A clinical trial is being initiated for patients with cancer using an intralesional anti-CD40 in combination with CIV rhIL-15. To translate IL-15-mediated increases in NK cells, we investigated combination therapy of IL-15 with anticancer monoclonal antibodies including rituximab in mouse models of EL-4 lymphoma transfected with human CD20 and with alemtuzumab (CAMPATH-1H) in a xenograft model of adult T cell leukemia (ATL). IL-15 enhanced the ADCC and therapeutic efficacy of both antibodies. These results provided the scientific basis for trials of IL-15 combined with alemtuzumab (anti-CD52) for patients with ATL (NCT02689453), with obinutuzumab (anti-CD20) for patients with CLL (NCT03759184), and with avelumab (anti-PD-L1) in patients with T-cell lymphoma (NCT03905135) and renal cancer (NCT04150562). In the first trial, there was elimination of circulating ATL and CLL leukemic cells in select patients.

Keywords: CD8 T cells; immunological checkpoints; immunotherapy of cancer; interleukin-15; natural killer cells.

Copyright © 2020 Waldmann, Dubois, Miljkovic and Conlon.

Figures

Figure 1
Figure 1
IL-15 agonists used in immunotherapy. IL-15 preparations in clinical use include rhIL-15 produced in Escherichia coli (–45), an IL-15N72D mutein (50), heterodimeric mammalian IL-15 (hetIL-15) (–54), RLI, a fusion protein consisting of IL-15 linked to the cytokine-binding (sushi) domain of IL-15R alpha (59). Anti-CD-20-RLI and anti-GD2-RLI are fusion proteins consisting of RLI linked to anti-CD20 or anti-GD2, respectively (55, 61). ALT-803 (Altor Pharmaceutical) represents a mutated N72D) IL-15 (asparagine replacing aspartic residue) linked to the sushi domain of IL-15R that is fused to an IgG-Fc fragment to increase in vivo survival (56, 57) and ALT-803 scaffold has been fused to 4 single- chains of the tumor-targeting monoclonal antibody rituximab (58).

References

    1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. (2012) 12:269–81. 10.1038/nri3191
    1. Waldmann TA, Miljkovic MD, Conlon KC. IL-15 (dys) regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer. J Exp Med. (2020) 217:e20191062 10.1084/jem.20191062
    1. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. (2014) 192:5451–8. 10.4049/jimmunol.1490019
    1. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, et al. . The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. (1994) 91:4940–4. 10.1073/pnas.91.11.4940
    1. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, et al. A lymphokine, provisionally designed interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. (1994) 91:4935–9. 10.1073/pnas.91.11.4935
    1. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. . Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. (1994) 264:965–8. 10.1126/science.8178155
    1. Waldmann TA, Tagaya Y. IL-15 cytokine. In Oppenheim JJ, Feldmann M, editors. The Cytokine Reference. A Compendium of Cytokines and Other Mediators of Host Defense. London: Academic Press. (2000). p. 213–24.
    1. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. (2001) 297:14–32. 10.1182/blood.V97.1.14
    1. Boyman O, Letourneau S, Krieg C, Spreng J. Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol. (2009) 39:2088–94. 10.1002/eji.200939444
    1. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. (2003) 3:269–79. 10.1038/nri1052
    1. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. . The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat Immunol. (2013) 14:1294–301. 10.1038/ni.2744
    1. Mayassi T, Jabri B. Human intraepithelial lymphocytes. Mucosal Immunol. (2018) 11:1281–9. 10.1038/s41385-018-0016-5
    1. Kwong B, Lazarevic V. T-bet orchestrates CD8αα IEL differentiation. Immunity. (2014) 41:169–71. 10.1016/j.immuni.2014.08.003
    1. Klose CS, Blatz K, d'Hargues Y, Hernandez PP, Kofoed-Nielsen M, Ripka, et al. . The transcription factor T-bet is induced by IL-15 and thymic agonist selection and controls CD8αα(+) intraepithelial lymphocyte development. Immunity. (2014) 41:230–43. 10.1016/j.immuni.2014.06.018
    1. Robinette ML, Bando JK, Song W, Ulland TK, Gilfillan S, Colonna M. IL-15 sustains IL-7R-independent ILC2 and ILC3 development. Nat Commun. (2017) 8:14601. 10.1038/ncomms14601
    1. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. . Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15 responsive IFN-γ-producing cells. Immunity. (2013) 38:769–81. 10.1016/j.immuni.2013.02.010
    1. Sciume G, Le MT, Gadina M. HiJAKing innate lymphoid cells? Front Immunol. (2017) 8:438. 10.3389/fimmu.2017.00438
    1. Bamford RN, Battiata AP, Waldmann TA. IL-15: the role of translational regulation in their expression. J Leukoc Biol. (1996) 59:476–80. 10.1002/jlb.59.4.476
    1. Bamford RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. Interleukin (IL)-15/IL-T production by the adult T-cell leukemia line HuT-102 is associated with a human T-cell lymphotrophic virus type 1 region/IL-15 fusion message that lacks many upstream AUGs that normally attenuate IL-15 mRNA translation. Proc Natl Acad Sci USA. (1996) 93:2897–902. 10.1073/pnas.93.7.2897
    1. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. (2006) 6:595–601. 10.1038/nri1901
    1. Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res. (2014) 20:2044–50. 10.1158/1078-0432.CCR-12-3603
    1. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, et al. . A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. (1997) 99:937–43. 10.1172/JCI119258
    1. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naïve, central memory and effector memory CD4+ T cells. Pathol Biol (Paris). (2003) 51:64–6. 10.1016/S0369-8114(03)00098-1
    1. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. (2006) 20:123–37. 10.1016/j.blre.2005.10.001
    1. Huntington ND. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol. (2014) 92:210–3. 10.1038/icb.2014.1
    1. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada H, Feigenbaum L, et al. . IL-2 induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA. (2000) 97:11445–50. 10.1073/pnas.200363097
    1. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R alpha recycles and presents IL-15 in trans to neighboring cells. Immunity. (2002) 17:537–47. 10.1016/S1074-7613(02)00429-6
    1. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15 and IL-7 in lymphoid homeostasis. Annu Rev Immunol. (2006) 24:657–79. 10.1146/annurev.immunol.24.021605.090727
    1. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. . Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. (2005) 105:721–7. 10.1182/blood-2003-12-4187
    1. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. (2007) 26:503–17. 10.1016/j.immuni.2007.03.006
    1. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. . IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. (2009) 206:25–34. 10.1084/jem.20082013
    1. Castillo EF, Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine. (2012) 59:479–90. 10.1016/j.cyto.2012.06.017
    1. Zanoni I, Spreafico R, Bodio C, Di Gioia M, Cigni C, Broggi A, et al. . IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep. (2013) 4:1235–49. 10.1016/j.celrep.2013.08.021
    1. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. (2011) 707:3–17. 10.1007/978-1-61737-979-6_1
    1. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. . Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. (1999) 17:221–53. 10.1146/annurev.immunol.17.1.221
    1. Snow AL, Pandiyan P, Zheng L, Krummey SM, Lenardo MJ. The power and the promise of restimulation-induced cell death in human immune diseases. Immunol Rev. (2010) 236:68–82. 10.1111/j.1600-065X.2010.00917.x
    1. Brentjens RJ, Latouche JB, Santos E, Marti F, Going MC, Lyddane C, et al. . Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. (2003) 9:279–86. 10.1038/nm827
    1. Munger W, DeJoy SQ, Jeyaseelan R, Sr, Torley LW, Grabstein KH, Eisenmann J, et al. . Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth-factor: comparison with interleukin-2. Cell Immunol. (1995) 165:289–93. 10.1006/cimm.1995.1216
    1. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. . IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8(+) T cells. Proc Natl Acad Sci USA. (2004) 101:1969–74. 10.1073/pnas.0307298101
    1. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, et al. . Interleukin-15 rescues tolerant CD8(+) T cells for use in adoptive immunotherapy of established tumors. Nat Med. (2006) 12:335–41. 10.1038/nm1359
    1. Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, et al. . IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood. (2011) 118:6845–8. 10.1182/blood-2011-09-377804
    1. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, et al. . Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. (2011) 117:4787–95. 10.1182/blood-2010-10-311456
    1. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. . Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. (2015) 33:74–82. 10.1200/JCO.2014.57.3329
    1. Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, et al. . A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res. (2018) 24:1525–35. 10.1158/1078-0432.CCR-17-2451
    1. Conlon KC, Potter EL, Pittaluga S, Lee CCR, Miljkovic MD, Fleisher TA, et al. IL-15 by continuous intravenous infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK-cell subset expansion. Clin Cancer Res. (2019) 25:4945–54. 10.1158/1078-0432.CCR-18-3468
    1. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, et al. . First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. (2018) 131:2515–27. 10.1182/blood-2017-12-823757
    1. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, et al. Phase I trial of ALT-803, a novel recombinant IL-15 complex, in patients with advanced solid tumors. Clin Cancer Res. (2018) 24:5552–61. 10.1158/1078-0432.ccr-18-0945
    1. Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, et al. . Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. (2018) 3:3. 10.1172/jci.insight.96219
    1. Dubois S, Conlon KC, Muller JR, Hsu-Albert J, Beltran N, Bryant BR, et al. . IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities. Cancer Immunol Res. (2017) 5:929–38. 10.1158/2326-6066.CIR-17-0279
    1. Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, et al. . Novel human interleukin-15 agonists. J Immunol. (2009) 183:3598–607. 10.4049/jimmunol.0901244
    1. Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, et al. . Characterization and favorable in vivo properties of heterodimeric soluble IL-15-IL-15Rα cytokine compared to IL-15 monomer. J Biol Chem. (2013) 288:18093–103. 10.1074/jbc.M113.461756
    1. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, et al. . Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. (2008) 283:4189–99. 10.1074/jbc.M705725200
    1. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, et al. . Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood. (2012) 120:e1–8. 10.1182/blood-2011-10-384362
    1. Bergamaschi C, Watson DC, Valentin A, Bear J, Peer CJ, Figg WD, Sr, et al. . Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. Cytokine. (2018) 108:213–24. 10.1016/j.cyto.2018.01.011
    1. Vincent M, Teppaz G, Lajoie L, Sole V, Bessard A, Maillasson M, et al. . Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs. (2014) 6:1026–37. 10.4161/mabs.28699
    1. Chen X, Liu B, Han K, Kong L, Noel T, Jeng EK, et al. Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model. J Immunother Cancer. (2015) 3(Suppl 2):P347 10.1186/2051-1426-3-S2-P347
    1. Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, et al. . Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. (2019) 17:29. 10.1186/s12967-019-1778-6
    1. Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther. (2016) 24:1312–22. 10.1038/mt.2016.88
    1. Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, et al. . Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 X IL-15R alpha fusion proteins. J Biol Chem. (2006) 281:1612–9. 10.1074/jbc.M508624200
    1. Bessard A, Solé V, Bouchard G, Quéméner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther. (2009) 8:2736–45. 10.1158/1535-7163.MCT-09-0275
    1. Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, et al. . Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer. (2013) 133:757–65. 10.1002/ijc.28059
    1. Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, et al. . IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA. (2018) 115:E10915–24. 10.1073/pnas.1811615115
    1. Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, et al. . IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat. (2011) 130:465–75. 10.1007/s10549-011-1360-2
    1. Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, et al. The IL-15-based ALT-803 complex enhances Fc gamma RIIIα-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res. (2016) 22:596–608. 10.1158/1078-0432.CCR-15-1419
    1. Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp Hematol. (2011) 39:1064–71. 10.1016/j.exphem.2011.08.006
    1. Liu B, Kong L, Han K, Hong H, Marcus WD, et al. . A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J Biol Chem. (2016) 291:23869–81. 10.1074/jbc.M116.733600
    1. Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA. (2009) 106:7513–8. 10.1073/pnas.0902637106
    1. Zhang ML, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, et al. . Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol. (2012) 188:6156–64. 10.4049/jimmunol.1102604
    1. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, et al. . Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA. (2012) 109:6187–92. 10.1073/pnas.1203479109
    1. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockage of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. (2010) 16:6019–28. 10.1158/1078-0432.CCR-10-1966
    1. Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N, et al. Development of a recombinant human IL-15. SIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomed Pharmacother. (2019) 112:10867 10.1016/j.biopha.2019.108677
    1. Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, et al. . Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade. Mol Ther. (2018) 26:2476–86. 10.1016/j.ymthe.2018.07.013
    1. Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer. (2019) 7:82. 10.1186/s40425-019-0551-y
    1. Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. (2018) 19:694–704. 10.1016/S1470-2045(18)30148-7
    1. Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, et al. . First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. (2019) 3:1970–80. 10.1182/bloodadvances.2018028332
    1. Miljkovic MD, et al. Interleukin-15 (IL-15) and alemtuzumab for relapsed/refractory mature T-cell malignancies [abstract]. In: Proceedings of the 2020 T-cell Lymphoma Forum. La Jolla, CA: (2018).
    1. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. . CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol. (2016) 17:816–24. 10.1038/ni.3470
    1. Bottino C, Dondero A, Moretta A, Castriconi R. CIS is a negative regulator of IL-15-mediated signals in NK cells. Transl Cancer Res. (2016) 5:(Suppl 4):S875–7. 10.21037/tcr.2016.10.79
    1. Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, et al. . Out-of-sequence signal 3 paralyzes primary CD4(+) T-cell-dependent immunity. Immunity. (2015) 43:240–50. 10.1016/j.immuni.2015.06.023
    1. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Health WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. (1998) 393:478–80. 10.1038/30996
    1. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. (1998) 393:474–8. 10.1038/30989
    1. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. (1998) 393:480–3. 10.1038/31002
    1. Li F, Ravetch JV. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. (2011) 333:1030–4. 10.1126/science.1206954
    1. Dahan R, Barnhart BC, Li F, Yamnjuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement. Cancer Cell. (2016) 29:820–31. 10.1016/j.ccell.2016.05.001
    1. Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, et al. . Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15 and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol. (2012) 188:3745–56. 10.4049/jimmunol.1102609
    1. Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. . TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog. (2016) 12:e1005349. 10.1371/journal.ppat.1005349
    1. Rifa'i M, Shi Z, Zhang SY, Lee YH, Shiku H, Isobe KI, et al. CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabeta TCR interaction and become IL-10-producing active regulatory cells. Int Immunol. (2008) 20:937–47. 10.1093/intimm/dxn052
    1. Desbois M, Le Vu P, Coutzac C, Marcheteau E, Beal C, Terme M, et al. IL-15 trans-signaling with the superagonist RL1 promotes effector/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists. J Immunol. (2016) 197:168–78. 10.4049/jimmunol.1600019

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa